Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts
04:24am, Thursday, 23'rd Apr 2026
Shares of Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) have been assigned an average recommendation of "Hold" from the five analysts that are covering the company, MarketBeat reports. One a
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
04:05pm, Wednesday, 22'nd Apr 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or th
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
07:30am, Thursday, 16'th Apr 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fulgent (FLGT) To Contact Him Directly To Discuss Their Options
Fulgent Genetics, Inc. (NASDAQ:FLGT) Sees Large Increase in Short Interest
03:13am, Tuesday, 31'st Mar 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 2,135,898 share
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
07:00pm, Wednesday, 25'th Mar 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning th
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
06:22pm, Monday, 23'rd Mar 2026
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) inve
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
08:00pm, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FL
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
06:00pm, Tuesday, 17'th Mar 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT). The investigation con
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
04:31pm, Tuesday, 17'th Mar 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
09:00am, Friday, 13'th Mar 2026
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulgent Genetics, Inc. (“Fulgent" or the "Company") (NASDAQ:FLGT) investors that the firm has initiated an investigation
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
10:00am, Thursday, 12'th Mar 2026
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advise
Fulgent Genetics: A Major Market Misconception
09:11am, Thursday, 12'th Mar 2026
Fulgent Genetics' Q4 2025 earnings report caused a massive share price decline of roughly 40%. The sell off has exacerbated the market's misconception about FLGT that already existed before the earnin
